Protocol Ledger

NCT05913037 · Phase III · ACTIVE NOT RECRUITING

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Interventional Phase III clinical trial protocol NCT05913037 sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-20 Enrollment: 167 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05913037
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)167 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05913037
Protocol FieldVerified Registry Value
NCT IdentifierNCT05913037
Consolidated Lead SponsorShanghai Fosun Pharmaceutical Industrial Development Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment167 participants (ACTUAL)
Registered Start Date2023-06-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI